EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8 + T cells

Yang Yang, Junjian He, Texi Liang, Kaiyi Li, Yao Lin, Hairu Wang, Wenwen Xi, Shusen Ye, Ding Qiu, Chunyang Xie, Yaxing Hao, Teming Li und 3 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2026-014897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yang Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical Universit…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Oncolytic Virotherapy, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Found for Distinguished Young Scholars of China, China Postdoctoral Science Foundation General Funding Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of combined chemotherapy and programmed cell death protein-1 (PD-1) immune checkpoint blockade (ICB) is constrained by the collateral cytotoxicity of chemotherapy toward proliferating tumor-specific CD8 + T (T TST ) cells, a population indispensable for antitumor immunity. This study aimed to overcome this limitation by targeting a potential chemotherapy-resistant immune cell reservoir.

Methods

By using the murine acutely resolved lymphocytic choriomeningitis virus (LCMV) infection and tumor models (colorectal cancer and melanoma), we characterized the susceptibility of CD8 + T TST and virus-specific bystander memory CD8 + T (T BYS ) cells to platinum-based chemotherapy-induced cytotoxicity. We next evaluated the antitumor efficacy and underlying mechanisms of combined chemotherapy and T BYS cell-targeted oncolytic virus therapy (OV-BYTE) in tumor-bearing mice with prior LCMV infection or SARS-CoV-2 vaccination. Finally, we assessed the antitumor efficacy of the triple combination regimen (including OV-BYTE, chemotherapy, and PD-1 ICB) in both murine colorectal cancer model and patient-derived colorectal cancer organoid.

Results

We first demonstrated that within the tumor microenvironment, CD8 + T TST cells are highly susceptible to platinum-based chemotherapy, whereas CD8 + T BYS cells constitute a quiescent, chemo-resistant population. Leveraging this, CD8 + T BYS -targeted OV-BYTE therapy synergized with chemotherapy to control tumorigenesis in multiple murine models. Mechanistically, this dual combination directly engaged the CD8 + T BYS cell reservoir for tumor killing, which was accompanied by the restoration of CD8 + T TST cell function via reduced apoptotic susceptibility and acquisition of a polyfunctional, effector-like state. Consequently, integrating OV-BYTE into the standard chemo-PD-1 ICB regimen resulted in improved antitumor efficacy in both preclinical and patient-derived tumor models.

Conclusions

Our study establishes the chemotherapy-resistant CD8 + T BYS cell niche as a pivotal therapeutic target. By engaging this target, OV-BYTE emerges as a potent combinatorial agent that successfully circumvents a core limitation of standard chemo-immunotherapy, thus offering a rationally designed and translatable strategy to advance combination cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesOncolytic VirotherapyImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorImmunotherapyAnimalsMiceHumansFemaleMice, Inbred C57BLCombined Modality TherapyCell Line, TumorLymphocytic choriomeningitis virus

Stichwörter der Autor:innen

ChemotherapyImmune Checkpoint InhibitorOncolytic virusT cellViral-specific T cells

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
  • Institute of Immunology, Third Military Medical University, Chongqing, China.
  • Institute for Immunology and Pathogenesis, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Department of Urology, South China Hospital of Shenzhen University, Shenzhen, Guangdong, China.
  • Department of General Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China chenxiangyu@cqmu.edu.cn li_teming@126.com yskedda0604@163.com yelilinlcmv@tmmu.edu.cn.
  • Cancer Center, Daping Hospital and Army Medical Center of PLA, Third Military Medical University, Chongqing, China chenxiangyu@cqmu.edu.cn li_teming@126.com yskedda0604@163.com yelilinlcmv@tmmu.edu.cn.

Förderung

  • National Natural Science Found for Distinguished Young Scholars of China
  • China Postdoctoral Science Foundation General Funding Program
  • National Natural Science Foundation of China
  • New Chongqing Youth Innovation Talent Program

Zitieren

APA

Yang, Y., He, J., Liang, T., Li, K., Lin, Y., Wang, H., Xi, W., Ye, S., Qiu, D., Xie, C., Hao, Y., Li, T., Yue, S., Ye, L., & Chen, X. (2026). Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8 + T cells. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-014897

Vancouver

Yang Y, He J, Liang T, Li K, Lin Y, Wang H, et al. Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8 + T cells. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-014897

BibTeX
@article{Yang2026,
  author = {Yang, Yang and He, Junjian and Liang, Texi and Li, Kaiyi and Lin, Yao and Wang, Hairu and Xi, Wenwen and Ye, Shusen and Qiu, Ding and Xie, Chunyang and Hao, Yaxing and Li, Teming and Yue, Shuai and Ye, Lilin and Chen, Xiangyu},
  title = {Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8 + T cells},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2026-014897}
}
Kostenlos starten →